Intervention: Ipilimumab 200 MG in 40 ML Injection
Found 6 matching trials
Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)
PHASE2
This study aims to evaluate the safety, tolerability and effectiveness of n...
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
PHASE2
This study will evaluate how safe the study drug is, how well patients tole...